Ai-powered Wearable Device Could Cut Parkinson’s Care Costs

Researchers uncover that continuous monitoring pinch nan STAT-ON™ wearable could toggle shape Parkinson’s management, redeeming millions successful attraction costs while enhancing patients’ value of life.

Study: Improving Parkinson’s illness guidance done wearable technology: A cost-benefit perspective. Image credit: Chinnapong/Shutterstock.com

STAT-ON™, a wearable medical device, whitethorn trim objective costs related to Parkinson’s illness guidance by continuously monitoring symptoms and optimizing curen adjustments, arsenic a caller study published in PLOS ONE reported.

Background

Parkinson’s illness (PD) is an age-related neurodegenerative disease, affecting astir 7 to 10 cardinal group globally. With expanding life expectancy and related emergence successful aging populations, particularly successful Western countries, nan prevalence of PD is expected to scope 17 cardinal successful 2040 and 25 cardinal successful 2050.

Such an exponential emergence successful prevalence, together pinch a precocious summation successful aesculapian costs, whitethorn importantly load nationalist healthcare systems. According to nan Parkinson’s Europe Association, nan societal costs of PD are astir €11.600 per diligent per year.

The test of PD is simply a analyzable process, and nary curable curen is presently available. Existing grounds indicates that astir 40% of PD cases are wrongly diagnosed successful existent objective practice, which is often frustrating for some patients and physicians.

In this context, galore neurologists propose that wearable aesculapian devices tin beryllium adjuvant successful continuously monitoring symptoms and acquiring applicable and reliable accusation from patients successful location environments. However, nan cost-effectiveness of introducing wearable devices successful objective believe remains mostly unknown.

In nan existent study, researchers explored nan modeled economical effect and imaginable objective usage of a wearable aesculapian device, STAT-ON™, to trim wide healthcare costs and amended value of life successful patients pinch PD.

STAT-ON™

STAT-ON™ is an artificial intelligence (AI)-powered waist-worn aesculapian instrumentality that monitors PD-related centrifugal symptoms during regular activities. It besides provides accusation astir patient’s medicine intake.

PD symptoms are often underestimated successful objective believe owed to subjective assessments and constricted consultation time. Clinical information is besides challenging, arsenic symptoms typically hap each 6 to 9 months and past only astir 20 minutes per visit. This deficiency of test subsequently leads to delayed curen adjustments and worsening of objective outcomes and patients’ value of life. 

STAT-ON™ is an extensively validated instrumentality that tin accurately observe cardinal centrifugal symptoms related to PD, supporting physicians successful curen decision-making and optimization. The instrumentality has shown comparable efficacy successful infirmary settings pinch different accepted tools, highlighting its objective usefulness successful assisting infirmary neurologists.

The patient’s information is securely stored successful nan instrumentality pinch due privacy, and information retrieval is managed done a healthcare professional’s smartphone app. After retrieval and study generation, nan information is deleted for instrumentality reuse pinch different patients.

One awesome advantage of STAT-ON™ complete wrist-worn devices is that its placement connected nan waist enables much precise monitoring of axial symptoms. On nan different hand, wrist-worn devices cannot accurately show centrifugal complications affecting nan trunk, little limbs, and neck.

STAT-ON™ wide view: The accompanying App enables configuring it astatine nan opening and generating nan last study aft nan observation. 

Cost-benefit study of STAT-ON™

The study utilized antecedently published and validated information to behaviour a cost-benefit study for introducing STAT-ON™ successful European healthcare systems for PD management.  

The study revealed that continuous monitoring and meticulous appraisal of PD symptoms utilizing STAT-ON™ helps optimize curen regimens, reducing hospitalizations and organization attraction costs.

Studies successful different European countries reported sizeable healthcare costs reductions done STAT-ON™ mediated discovery of mean and precocious symptoms successful patients pinch PD. Specifically, nan study estimated imaginable costs reductions of up to €137.8 cardinal successful Germany and €19 cardinal successful Sweden erstwhile STAT-ON™ is utilized to observe precocious PD symptoms.

These benefits support nan inclusion of STAT-ON™ successful objective practice. Although this inclusion whitethorn summation medicine expenses owed to nan medicine of highly costly medicines for precocious illness stages, nan betterment successful patients’ value of life and simplification successful nonstop healthcare expenses will thief offset nan costs of medications.  

Utility of STAT-ON™

STAT-ON™ was developed to trim healthcare costs and amended patients' value of life. This instrumentality tin besides service arsenic a telemedicine instrumentality for distant monitoring of PD patients. Telemedicine studies involving STAT-ON™ person reported important betterment successful daily-life activities, beingness activity, depression, apathy, activity difficulties, balance, and frailty successful PD patients.

Besides objective benefits, STAT-ON™ tin support basal investigation by providing information connected PD patients’ centrifugal symptoms and regular activities. By ensuring personalized monitoring, nan instrumentality tin besides trim subordinate drop-out and amended adherence, strengthening nan value of objective trials.

Regarding curen optimization, STAT-ON™ tin assistance physicians successful identifying patients suitable for second-line therapies, specified arsenic heavy encephalon stimulation, continuous dopaminergic infusions, and different precocious treatments recommended for patients who do not respond to first-line medications.

Overall, nan study's model-based cost-benefit study supports including STAT-ON™ successful objective believe for PD management. However, nan study relies connected economical information from various European healthcare systems, which disagree successful structure, reimbursement policies, and aesculapian attraction costs, perchance limiting nan generalizability of nan findings.

Furthermore, nan study addressed nonstop aesculapian costs related to PD. Still, it did not thoroughly see indirect costs specified arsenic caregiver load and mislaid productivity, which whitethorn impact nan observed cost-effectiveness of STAT-ON™.

Previous validation studies wished the efficacy of STAT-ON™ successful detecting PD symptoms. Further large-scale objective tests are required to corroborate nan effectiveness crossed different diligent populations.

Download your PDF transcript now!